What is the difference between FDA-approved and FDA-cleared for hair loss treatments?
Before comparing treatments, the terminology needs clarifying because it is systematically misused in product marketing.
FDA-approved drugs have completed the full New Drug Application (NDA) process. This requires pre-clinical data, phase I through phase III clinical trials demonstrating safety and efficacy for the specific indication, and FDA review of the full data package. Finasteride 1 mg (Propecia) and topical minoxidil are FDA-approved drugs for androgenetic alopecia.
FDA-cleared deviceshave passed through the 510(k) premarket notification process. 510(k) clearance means the device is substantially equivalent to a legally marketed predicate device — it does not require clinical trials demonstrating efficacy for the specific use. Certain laser combs, helmets, and caps have received 510(k) clearance for hair loss, which is a weaker evidential standard than drug approval. When a device company says “FDA-cleared,” they are not claiming the same regulatory bar as a drug.
This distinction shapes how you should interpret evidence claims across the treatment landscape.
| Treatment | Regulatory status | Evidence standard | Typical effect | Rx required? |
|---|---|---|---|---|
| Finasteride 1 mg | FDA-approved (men) | Phase III RCTs | Hair preservation + regrowth; DHT suppressed ~60–70% | Yes |
| Topical minoxidil (2% / 5%) | FDA-approved (men & women) | Controlled trials | Hair density increase; anagen-phase extension | No (OTC) |
| Oral minoxidil (low-dose) | Off-label use | Observational + RCTs | Similar to topical; systemic convenience | Yes |
| LLLT devices (cap/comb/helmet) | FDA-cleared (510k device) | RCTs (modest effect) | Modest hair count increase; best as adjunct | No |
| PRP (platelet-rich plasma) | Not FDA-approved or cleared | Small RCTs; heterogeneous | Promising but limited long-term data | In-person procedure |
Finasteride (Propecia / generic): the gold standard for male pattern hair loss
Finasteride 1 mg is an FDA-approved oral medication that suppresses dihydrotestosterone (DHT) — the androgen that drives follicle miniaturization in male androgenetic alopecia — by approximately 60 to 70 percent. It targets the root hormonal cause of the most common form of male hair loss.
The pivotal registration trials enrolled more than 1,500 men and showed that finasteride significantly increased hair counts versus placebo at one and two years. A five-year open-label extension found that the majority of men on finasteride maintained or improved hair density compared to baseline, while the untreated group continued to lose hair.
Finasteride requires a prescription. Known side effects include a low but real incidence of sexual adverse effects (reduced libido, erectile dysfunction, ejaculate volume changes) that resolve with discontinuation in most cases. A clinician evaluation is appropriate before starting. Finasteride is contraindicated in women who are or may become pregnant.
“FDA-cleared” signals only substantial equivalence to a predicate device — not the controlled-trial efficacy bar that “FDA-approved” drugs must clear.
Minoxidil: topical and oral options
Minoxidil is FDA-approved in topical form (2% and 5% solutions, 5% foam) for androgenetic alopecia in both men and women. Oral minoxidil is prescribed off-label for hair loss at low doses (typically 0.25 mg to 5 mg daily depending on sex and tolerance) by clinicians familiar with its cardiovascular profile.
Minoxidil’s mechanism differs from finasteride. It does not suppress DHT. Instead, it is believed to work as a potassium channel opener, increasing scalp vasodilation and blood flow to hair follicles. It also appears to prolong the anagen (active growth) phase of the hair cycle. Critically, minoxidil does not address the hormonal driver of androgenetic alopecia, which is why combination with finasteride is common in clinical practice.
Topical minoxidil’s most common side effects are local: scalp irritation and, with the propylene glycol formulations, contact dermatitis in some users. Topical absorption is low. Oral minoxidil at low doses has a different systemic profile including fluid retention and hypertrichosis (body hair increase); a cardiovascular review is appropriate at prescription.
Low-level laser therapy (LLLT): FDA-cleared devices
Multiple low-level laser therapy devices — ranging from helmet caps to handheld combs — have received FDA 510(k) clearance for the promotion of hair growth. To be clear on regulatory status: clearance via 510(k) means substantial equivalence to a predicate, not demonstrated efficacy through controlled trials.
With that caveat, controlled trials do exist for several LLLT devices. Several randomized, placebo-controlled studies have reported modest improvements in hair counts and density in men and women with androgenetic alopecia after 16 to 26 weeks of device use. The effect sizes reported are generally smaller than those for finasteride or minoxidil. LLLT is commonly positioned as an adjunct rather than a primary monotherapy.
Proposed mechanisms include mitochondrial stimulation via photobiomodulation, which may support follicle metabolism and extend the anagen phase. Safety profiles in trials have been favorable; LLLT does not appear to carry systemic risk when used as directed.
Platelet-rich plasma (PRP): promising but not FDA-approved
Platelet-rich plasma involves drawing a patient’s blood, centrifuging it to concentrate platelets and growth factors, and injecting the resulting plasma into the scalp. PRP is not FDA-approved for hair loss as a drug or device. The centrifuge devices used to prepare PRP may carry FDA clearance as medical devices, but PRP itself operates as an autologous biologic outside the standard drug approval pathway.
The clinical evidence for PRP is more preliminary than for finasteride or minoxidil. Randomized controlled trials have reported improvements in hair density and follicle count, but study sizes are generally small, protocols vary considerably across trials (platelet concentration, preparation method, injection frequency), and long-term maintenance data is limited. A meta-analysis of PRP for androgenetic alopecia concluded positive overall effects but noted methodological heterogeneity as a significant limitation.
PRP requires in-person administration at a clinic equipped for the procedure. It is typically not available through telehealth-only platforms and is more often used in combination with first-line therapies.
Which hair loss products do not have meaningful evidence?
The hair loss market is saturated with products that claim FDA-related legitimacy but do not have it:
- Biotin supplements: FDA has issued warnings about biotin interference with lab tests. No controlled trial has demonstrated biotin supplementation reverses androgenetic alopecia in individuals without a biotin deficiency.
- DHT-blocking shampoos: Topical formulations with saw palmetto or ketoconazole have some supportive data, but effect sizes are small and evidence is not at the same level as oral finasteride.
- Uncleared scalp devices: Many devices marketed for hair growth have not cleared any FDA pathway and rely on testimonials rather than controlled data.
If a product cannot cite an FDA approval number or a 510(k) clearance number, its “FDA-cleared” claims are not verifiable.
How do you choose? A framework for clinical decision-making
Hair loss treatment is not one-size-fits-all. Variables a clinician will consider include sex (finasteride has contraindications in women), the pattern and stage of hair loss, comorbid conditions, and patient preferences about side effect risk.
A common clinical approach for men with male-pattern hair loss involves starting with finasteride plus topical minoxidil — the two most evidence-backed options — and reassessing at six and twelve months. LLLT can be added as an adjunct if tolerated and the patient is motivated. PRP may be appropriate for those who do not respond to first-line treatment or who want an in-office procedure option.
For women, topical minoxidil is typically first-line. Oral minoxidil at low doses is used off-label. Spironolactone (an anti-androgen) is sometimes prescribed by clinicians for female pattern hair loss. Finasteride is used off-label in postmenopausal women in some clinical contexts.
Frequently asked questions
What is the difference between FDA-approved and FDA-cleared for hair loss?
FDA-approved drugs (finasteride, minoxidil oral) have gone through the full New Drug Application process with efficacy and safety data from clinical trials. FDA-cleared devices (certain laser combs and helmets) have gone through the 510(k) process, which establishes substantial equivalence to a predicate device — a different and generally less demanding standard than drug approval.
Which FDA-approved hair loss treatment is most effective?
Head-to-head data is limited. Finasteride 1 mg addresses the hormonal root cause (DHT) and has shown hair count preservation and regrowth in controlled trials. Minoxidil increases scalp blood flow and prolongs the hair growth phase. Combining both is common in clinical practice and supported by evidence for greater effect than either alone.
Does low-level laser therapy (LLLT) work for hair loss?
Several LLLT devices have FDA clearance for hair loss as a cosmetic device. Some randomized controlled trials show modest improvements in hair density. The effect size is generally smaller than finasteride or minoxidil, and results vary. LLLT is sometimes used as an adjunct rather than a standalone treatment.
Is PRP for hair loss FDA-approved?
Platelet-rich plasma (PRP) is not FDA-approved for hair loss. Centrifuge devices used to prepare PRP may be FDA-cleared as medical devices, but PRP itself is an autologous biologics procedure that falls outside the standard drug approval pathway. Evidence for efficacy is promising but not yet as robust as for finasteride or minoxidil.
Can I combine multiple hair loss treatments?
Combination therapy is common and supported by clinical evidence. Finasteride plus topical minoxidil is the most studied combination. Adding LLLT or PRP as adjuncts is done in clinical practice, though combination trial data is more limited. A clinician can assess which combination makes sense for your presentation.